SPROHealthcare · BiotechnologyThe 2 Wall Street analysts covering Spero Therapeutics, Inc. hold a median 12-month price target of $5 — +331.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 3 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Spero Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (100): Sales and profits are climbing, and climbing faster than before.
Momentum (22): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SPRO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +331.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $5.00 → $6.00 |
| 30 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | $5.00 |
| 30 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Dec 2024 | Evercore ISI Group | Downgrade | In-Line | — |
| 2 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Nov 2024 | TD Cowen | Downgrade | Hold | — |
| 15 Nov 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 4 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Aug 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 6 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Aug 2024 | TD Cowen | Upgrade | Buy | — |
| 16 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Apr 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 18 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Nov 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Sept 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Aug 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 1 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 July 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SPRO appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 5 Oct 2026, Spero Therapeutics, Inc. returned −43.4% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 60% of US stocks
Cheaper than 59% of US stocks
Cheaper than 52% of US stocks
Cheaper than 56% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 71% of US stocks
Higher than 78% of US stocks
Higher than 80% of US stocks
Higher than 86% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Spero Therapeutics, Inc. has a market value of $69.3M and an enterprise value of $20.6M.
Revenue in the twelve months to 30 June 2026: $43.0M. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: $7.4M, a 17.2% net margin.
Diluted earnings per share, trailing twelve months: $0.11.
Free cash flow in the twelve months to 30 June 2026: $19.6M.
Trailing P/E: 8.4×; forward P/E: −1.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Spero Therapeutics, Inc. employs 25 people — $1.7M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Spero Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
A researcher at an anti-plague facility in Siberia's Irkutsk region died after exposure to Yersinia pestis, prompting Russian officials to quarantine regional hospitals and isolate nearly 200 contacts.
Why it matters — The outbreak could heighten attention on under-the-radar biopharma and infectious-disease companies, a space where SPRO watchers would find relevance.
Spero Therapeutics announced that its Compensation Committee approved grants made on October 1, 2026, of an aggregate of 233,000 restricted stock unit awards and 323,000 stock options to new employees under the company's 2019 Inducement Equity Incentive Plan. The awards are inducement grants made in accordance with Nasdaq Listing Rule 5635(c)(4).
Why it matters — SPRO watchers would care because the new-employee equity grants signal hiring and potential dilution, while reflecting the company's ongoing operations under its inducement plan.
Spero Therapeutics announced that its Compensation Committee approved an inducement grant on September 1, 2026, consisting of 102,000 restricted stock unit awards and 67,600 stock options for new employees under the company's 2019 Inducement Equity Incentive Plan.
Why it matters — SPRO watchers may care because this routine equity grant is part of the company's standard employee incentive program and signals new hires joining the biopharmaceutical firm.
Spero Therapeutics announced that its President and Chief Executive Officer, Esther Rajavelu, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The announcement was made on September 2, 2026.
Why it matters — A SPRO watcher would care because the CEO's presentation at a major investment conference offers an opportunity for the company to communicate its clinical-stage programs in immunology and inflammation to investors.
Spero Therapeutics published the transcript of its Q2 2026 earnings call on Seeking Alpha. The transcript covers the company's second-quarter 2026 financial results and management commentary.
Why it matters — SPRO watchers can review the earnings call transcript for management's detailed discussion of the company's quarterly performance and outlook.
The 2 Wall Street analysts covering Spero Therapeutics, Inc. have a median 12-month price target of $5, with estimates ranging from $4 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Spero Therapeutics, Inc., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Spero Therapeutics, Inc. 89 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Oct 2026, Spero Therapeutics, Inc. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (100 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +331.0% from the last close, and Ticker Nerd's factor model ranks Spero Therapeutics, Inc. 89 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Spero Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SPRO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $6 over the next 12 months.
Spero Therapeutics, Inc. returned -43.4% over the 12 months to 5 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for multi-drug resistant bacterial infections and rare diseases.
The most recent item we track (Invezz, 5 Oct 2026): "Russian plague outbreak could boost these under-the-radar pharma stocks". A researcher at an anti-plague facility in Siberia's Irkutsk region died after exposure to Yersinia pestis, prompting Russian officials to quarantine regional hospitals and isolate nearly 200 contacts.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for multi-drug resistant bacterial infections and rare diseases. Spero Therapeutics advances a pipeline of product candidates aimed at serious infectious and immune-mediated conditions, including tebipenem pivoxil, an oral carbapenem antibiotic for complicated urinary tract infections, SPR720 for nontuberculous mycobacterial pulmonary disease, SPR206 for difficult Gram-negative infections, and SP001 for immune-mediated disease. The company’s work centers on addressing high unmet medical needs in hospital, outpatient, and specialty care settings through novel small-molecule and biologic therapies. Headquartered in Cambridge, Massachusetts, Spero Therapeutics plays a role in the biopharmaceutical market by focusing on differentiated medicines for patients with limited treatment options.
CEO Ms. Esther P. Rajavelu · 25 employees · United States · https://sperotherapeutics.com
